Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer

Open Access

Peer-reviewed

Research Article

Jieun Lee ,

* E-mail: befamiliar@catholic.ac.kr

Affiliations Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, Cancer Research Institute, The Catholic University of Korea, Seoul, Korea
⨯
Hyun Ho Kim,

Affiliation Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
⨯
Sang Mi Ro,

Affiliation Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
⨯
Ji Hyun Yang

Affiliation Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
⨯

Reader Comments (0)

Breast cancer
Is the Subject Area "Breast cancer" applicable to this article?

Thanks for your feedback.
Cancer chemotherapy
Is the Subject Area "Cancer chemotherapy" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Chemotherapy
Is the Subject Area "Chemotherapy" applicable to this article?

Thanks for your feedback.
Toxicity
Is the Subject Area "Toxicity" applicable to this article?

Thanks for your feedback.
Gastrointestinal cancers
Is the Subject Area "Gastrointestinal cancers" applicable to this article?

Thanks for your feedback.
Metastasis
Is the Subject Area "Metastasis" applicable to this article?

Thanks for your feedback.
Chemotherapeutic agents
Is the Subject Area "Chemotherapeutic agents" applicable to this article?

Thanks for your feedback.